Rotavirus Drug Development Pipeline Study, H2 2018
Rotavirus Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Rotavirus pipeline products.
DISEASE OVERVIEW
Rotavirus virus symptoms include diarrhea, nausea and stomach pain in children. The infection results in dehydration, often requiring children to be admitted in hospital. In humans, the disease is transmitted primarily through contamination with infected objects and human-to-human via fecal oral route.
Irrespective of geography and economy, children across countries worldwide are affected by rotavirus infection. WHO estimates around 2 million children are hospitalized annually and 453,000 children face death.
Children typically are affected with initial rotavirus infections between 6 months and 3 years. In particular, underweighted children and low immunity children have high prevalence of rotavirus infections. Most prominent rotavirus genotypes are G1P, G2P, G3P, G4P, and G9P.
RotaTeq and Rotarix vaccines are being currently administered for prevention of rotavirus infections. No specific drugs are administered to patients but rehydration therapies are given through oral and intravenous routes.
Both vaccines and treatment solutions are being developed by leading pharmaceutical companies. Currently 11 companies are actively participating in the list, which include%li%Bharat Biotech International Ltd, Biological E Ltd, Curevac AG, GlaxoSmithKline Plc, Medicago Inc, Mitsubishi Tanabe Pharma Corporation, MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, Murdoch Children’s Research Institute, Program for Appropriate Technology in Health, Serum Institute of India Ltd and UMN Pharma Inc.
REPORT DESCRIPTION
The Rotavirus pipeline guide presents complete overview of drugs currently being developed for Rotavirus. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rotavirus pipeline candidate.
Research and Development progress along with latest news related to each of the Rotavirus pipeline candidates is included.
Major companies participating in therapeutic development of Rotavirus are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Rotavirus from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rotavirus clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Rotavirus pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF ROTAVIRUS PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Rotavirus virus symptoms include diarrhea, nausea and stomach pain in children. The infection results in dehydration, often requiring children to be admitted in hospital. In humans, the disease is transmitted primarily through contamination with infected objects and human-to-human via fecal oral route.
Irrespective of geography and economy, children across countries worldwide are affected by rotavirus infection. WHO estimates around 2 million children are hospitalized annually and 453,000 children face death.
Children typically are affected with initial rotavirus infections between 6 months and 3 years. In particular, underweighted children and low immunity children have high prevalence of rotavirus infections. Most prominent rotavirus genotypes are G1P, G2P, G3P, G4P, and G9P.
RotaTeq and Rotarix vaccines are being currently administered for prevention of rotavirus infections. No specific drugs are administered to patients but rehydration therapies are given through oral and intravenous routes.
Both vaccines and treatment solutions are being developed by leading pharmaceutical companies. Currently 11 companies are actively participating in the list, which include%li%Bharat Biotech International Ltd, Biological E Ltd, Curevac AG, GlaxoSmithKline Plc, Medicago Inc, Mitsubishi Tanabe Pharma Corporation, MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, Murdoch Children’s Research Institute, Program for Appropriate Technology in Health, Serum Institute of India Ltd and UMN Pharma Inc.
REPORT DESCRIPTION
The Rotavirus pipeline guide presents complete overview of drugs currently being developed for Rotavirus. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rotavirus pipeline candidate.
Research and Development progress along with latest news related to each of the Rotavirus pipeline candidates is included.
Major companies participating in therapeutic development of Rotavirus are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Rotavirus from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rotavirus clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Rotavirus pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF ROTAVIRUS PIPELINE REPORT INCLUDES
- Panorama of Rotavirus pipeline markets including statistics on therapeutic drugs and companies involved
- Rotavirus Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Rotavirus pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Rotavirus pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Rotavirus pipeline therapeutics
- Get clear understanding of the entire Rotavirus pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Rotavirus pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Rotavirus Pipeline include-
Number of Companies with Rotavirus projects in pre-clinical Development-
Number of Companies with Rotavirus projects in Clinical Development-
Rotavirus Pipeline Companies based in Americas
Rotavirus Pipeline Companies based in Europe
Rotavirus Pipeline Companies based in Asia Pacific
Rotavirus Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Rotavirus Pipeline Agents in pre- clinical/Discovery stage of Development
Rotavirus Pipeline Agents in Clinical Development stage
Rotavirus Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Rotavirus Pipeline agents
II. INSIGHTS INTO ROTAVIRUS PIPELINE
1. Disease Overview
Introduction to Rotavirus
Symptoms and Causes of Rotavirus
Treatment or Prevention Options for Rotavirus
Other Details
2. Phase wise Pipeline Compounds
Rotavirus Pipeline- Pre- Clinical/Discovery stage Drugs
Rotavirus Pipeline- Phase 1 stage Drugs
Rotavirus Pipeline- Phase 2 stage Drugs
Rotavirus Pipeline- Phase 3 stage Drugs
Rotavirus Pipeline- Pre-Registration stage Drugs
3. Company wise Rotavirus Pipeline Compounds
4. Rotavirus Pipeline by Mechanism of Action
III. ROTAVIRUS PIPELINE COMPOUND DETAILS
EV71 vaccine
ROTAVAC 5CM
tetravalent inactivated rotavirus vaccine
rotavirus vaccine
Rotavirus prophylaxis vaccine
Rotavirus VLP vaccine
Rotavirus Infections
Heat Stable Rotavirus Vaccine
RV3-BB
P2-VP8-P[8] Subunit Rotavirus Vaccine
rotavirus serotypes (G1, G2, G3, G4, and G9) vaccine
UMN-103
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. ROTAVIRUS PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech International Ltd
Biological E Ltd
Curevac AG
GlaxoSmithKline Plc
Medicago Inc
Mitsubishi Tanabe Pharma Corporation
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Serum Institute of India Ltd
UMN Pharma Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL ROTAVIRUS PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Rotavirus Pipeline include-
Number of Companies with Rotavirus projects in pre-clinical Development-
Number of Companies with Rotavirus projects in Clinical Development-
Rotavirus Pipeline Companies based in Americas
Rotavirus Pipeline Companies based in Europe
Rotavirus Pipeline Companies based in Asia Pacific
Rotavirus Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Rotavirus Pipeline Agents in pre- clinical/Discovery stage of Development
Rotavirus Pipeline Agents in Clinical Development stage
Rotavirus Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Rotavirus Pipeline agents
II. INSIGHTS INTO ROTAVIRUS PIPELINE
1. Disease Overview
Introduction to Rotavirus
Symptoms and Causes of Rotavirus
Treatment or Prevention Options for Rotavirus
Other Details
2. Phase wise Pipeline Compounds
Rotavirus Pipeline- Pre- Clinical/Discovery stage Drugs
Rotavirus Pipeline- Phase 1 stage Drugs
Rotavirus Pipeline- Phase 2 stage Drugs
Rotavirus Pipeline- Phase 3 stage Drugs
Rotavirus Pipeline- Pre-Registration stage Drugs
3. Company wise Rotavirus Pipeline Compounds
4. Rotavirus Pipeline by Mechanism of Action
III. ROTAVIRUS PIPELINE COMPOUND DETAILS
EV71 vaccine
ROTAVAC 5CM
tetravalent inactivated rotavirus vaccine
rotavirus vaccine
Rotavirus prophylaxis vaccine
Rotavirus VLP vaccine
Rotavirus Infections
Heat Stable Rotavirus Vaccine
RV3-BB
P2-VP8-P[8] Subunit Rotavirus Vaccine
rotavirus serotypes (G1, G2, G3, G4, and G9) vaccine
UMN-103
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. ROTAVIRUS PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech International Ltd
Biological E Ltd
Curevac AG
GlaxoSmithKline Plc
Medicago Inc
Mitsubishi Tanabe Pharma Corporation
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Serum Institute of India Ltd
UMN Pharma Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL ROTAVIRUS PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
